INVO Fertility Posts 23% Q1 Revenue Growth and Zeroes Out Series C-2 Liabilities
IVF•INVO Fertility’s Q1 revenue rose 23% to $2.02 million, driven by organic clinic initiatives and the Family Beginnings acquisition. The company eliminated $2.4M in Series C-2 Preferred Stock and $1.9M in warrant liabilities, boosting stockholders’ equity 108% to $15.0 million and raising cash to $4.9 million.
1. Q1 2026 Financial Highlights
INVO Fertility reported Q1 revenue of $2.02 million, a 23% increase year-over-year, with consolidated clinic revenue up 22% to $1.98 million. Net loss from continuing operations widened to $5.5 million due to a $3.8 million non-cash warrant revaluation, while adjusted EBITDA was $(1.26) million.
2. Capital Structure and Liquidity Improvements
The company converted or retired all Series C-2 Preferred Stock and eliminated $1.9 million in warrant liabilities, reducing total liabilities by 26% to $9.6 million. Stockholders’ equity doubled to $15.0 million and cash balances rose to $4.9 million, bolstered by $7.1 million in warrant exercises.
3. Expansion of Clinic Platform
In February, INVO completed the acquisition of Family Beginnings P.C., adding its fourth U.S. fertility clinic and enhancing Midwest presence. This partial-quarter acquisition, combined with organic clinic initiatives, underpinned the revenue growth and diversified the company’s service offerings, including its INVOcell solution.
4. Strategic Investments Supporting Growth
During Q1, INVO Fertility increased staffing across operations, human resources, and finance to support further clinic expansions and acquisitions. These upfront investments impacted adjusted EBITDA but are expected to improve operational scalability and drive profitability throughout 2026.
